NANOCARRIER BASED INTRALYMPHATIC IMAGING AND THERAPY FOR MELANOMA

$141,012P20FY2009RRNIH

University Of Kansas Lawrence, Lawrence KS

Investigators

Linked publications & trials

Paper 38886037 Paper 29581860 Paper 29155177 Paper 28631436 Paper 26542767 Paper 26051358 Paper 25942583 Paper 25756513 Paper 25374921 Paper 25283328 Paper 25225870 Paper 25176160 Paper 24763440 Paper 24718901 Paper 24699334 Paper 24496625 Paper 24273633 Paper 24098060 Paper 24091600 Paper 24014025 Paper 23814632 Paper 23811326 Paper 23784800 Paper 23474329 Paper 23462932 Paper 23319596 Paper 23254267 Paper 23252848 Paper 23231932 Paper 23158190 Paper 23129310 Paper 23099792 Paper 23036966 Paper 22935373 Paper 22934946 Paper 22806441 Paper 22494444 Paper 22389453 Paper 22281420 Paper 22125584 Paper 22098611 Paper 21996741 Paper 21949558 Paper 21823128 Paper 21806374 Paper 21718728 Paper 21669240 Paper 21644824 Paper 21629779 Paper 21456066 Paper 21314099 Paper 21308712 Paper 21254383 Paper 21134556 Paper 21079245 Paper 20962590 Paper 20920606 Paper 20809896 Paper 20726569 Paper 20634288 Paper 20577568 Paper 20448812 Paper 20403395 Paper 20401396 Paper 20385908 Paper 20363303 Paper 20345214 Paper 20303585 Paper 20233900 Paper 20228053 Paper 20197389 Paper 20181281 Paper 20164583 Paper 20161351 Paper 20161276 Paper 20138387 Paper 20112345 Paper 20046941 Paper 20046916 Paper 20026904 Paper 19969129 Paper 19960530 Paper 19958949 Paper 19897736 Paper 19894718 Paper 19883077 Paper 19862331 Paper 19818339 Paper 19763953 Paper 19743894 Paper 19661621 Paper 19603087 Paper 19563270 Paper 19538164 Paper 19505109 Paper 19429421 Paper 19421144 Paper 19415471 Paper 19386275 Paper 19383440

Abstract

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The rate of melanoma skin cancer is increasing yearly with 60000 new cases in 2007 in the US alone. Melanoma is highly curable if treated before it has spread from the primary site on the skin, but 5-year survival rates drop to only 29% once disease has spread to lymph nodes and fall even lower (down to 7%) if tumors metastasize to major organs. The goal of this proposal is to devetop and optimize a new drug-delivery and imaging platform for melanoma staging and treatment. Since melanomas naturally spread initially through local lymphatic channels and lymph nodes, this delivery and imaging system will specifically target the lymphatics. Using nanotechnology, hyaluronic acid, a compound naturally found in the body, is combined with drugs like melphalan normally used in regional therapy for melanoma, and delivered through the lymphatics. By lymphatic drug-delivery, the tumor is treated in a targeted manner, decreasing the amount of drug absorbed systemically which should result in a lower toxicity profile than the way it is currently administered. In addition to treating early melanoma through the lymphatics, this nanocarrier can be combined with gadolinium and imaged by MRI. Utilizing intralyrnphatic delivery for a contrast agent, this proposal will also explore novel ways to image lymphatically spread tumors such as melanoma. If successful, this research will result in an improved method for treating and imaging early to intermediate stage melanoma avoiding the morbidity of current treatment modalities and advancing the field of cancer imaging and therapeutics for lymphatically spread tumors.

View original record on NIH RePORTER →